Navigation Links
Mesa Labs Increases Quarterly Dividend
Date:11/7/2012

LAKEWOOD, Colo., Nov. 7, 2012 /PRNewswire/ -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, "Mesa" or the "Company") today announced that our Board of Directors has declared a regular quarterly dividend of $0.14 per share of common stock, up from $0.13 per share last quarter.  The dividend will be payable December 14, 2012, to shareholders of record on November 30, 2012.

Since going public in 1984, we have maintained strong cash positions and have continued to build our balance sheet through steady earnings growth.  The increase in the regular quarterly dividend rate from $0.13 to $0.14 per common share represents an eight percent increase from the previous dividend rate, and a 180 percent increase since initiation of the quarterly dividend policy in December 2003.

About Mesa Laboratories, Inc.

We are organized into two divisions across four physical locations.  Our Instruments division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, semiconductor and petrochemical industries.  Our Biological Indicators division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, gas, hydrogen peroxide and radiation, in the hospital, dental, medical device and pharmaceutical industries.

Forward Looking Statements

This press release may contain information that constitutes "forward-looking statements." Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not
'/>"/>

SOURCE Mesa Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Physician-Friendly Coding and Compliance Tool Increases Accuracy and Documentation of Patient Charges
2. Boston Scientific Increases Longevity Projections for Its U.S. Defibrillators
3. Survey: Hospital Executives Nationwide Facing Operating Room Case Volume Increases, Seeking Greater Efficiency through Healthcare Information Technology (HIT)
4. AMILPAR - Revenues Grow 18% and EBITDA Increases 19% in 1H12
5. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
6. Group Florence Nightingale Increases Radiosurgery Profile with Acquisition of Turkeys First Leksell Gamma Knife Perfexion System
7. Glenmarks Consolidated Revenue Increases by 18.9% to Rs. 12551.9 Mn for Q2 FY12-13
8. Watson Third Quarter 2012 Non-GAAP Diluted EPS Increases 24% to $1.35; Net Revenue Increases 19% to $1.29 Billion
9. Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Heska Announces Quarterly Dividend of $0.10 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... --  Millar, Inc. , a leader in catheter-based and ... of Craig Thummel , President/CEO and member of ... to the Company. The Company also announced its leadership ... Executive Management team as his successors. The Board of ... of Sales and Marketing, as President, and also a ...
(Date:6/30/2015)... 2015 Dipexium Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of Locilex® (pexiganan ... previously announced underwritten public offering of 1,480,000 shares ... over-allotment option in full to purchase an additional ... net proceeds to Dipexium are expected to be ...
(Date:6/30/2015)... , June 24, 2015 ... the addition of the "Global Array Instruments ... The global array instruments market to grow ... period 2014-2019 The global array instruments market ... protein microarrays, and others including tissue microarrays and ...
Breaking Medicine Technology:Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Dipexium Announces Closing of Public Offering of Common Stock 2Dipexium Announces Closing of Public Offering of Common Stock 3Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2
... Biosciences, Inc., a privately held company leading the development ... Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and ... College of Chest Physicians (ACCP) Coagulation and Heart Disease ...  The abstract is titled "Sustained Inhibition of Factor IXa ...
... JEDDAH, Saudi Arabia, Nov. 2, 2010 The Saudi ... it has signed an agreement with Varian Medical Systems ... for magnetic resonance-guided radiation therapy (MRgRT™). Under ... treatment solution that combines IMRIS, unique movable magnetic resonance ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 2Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 3Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 2Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 3Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 4
(Date:6/30/2015)... ... June 30, 2015 , ... ... Rehab”. The video focuses on the rehab center’s patients and their experiences at ... the best quality of services available. Each patient attests to the high rating, ...
(Date:6/30/2015)... ... June 30, 2015 , ... According to a June 15th report ... study how sensory stimuli can be used to “decrease children’s anxiety and negative responses ... with autism, will compare patient experience in a “typical dental environment” with one that ...
(Date:6/30/2015)... Long Beach, CA (PRWEB) , ... June 30, 2015 , ... ... Sea Skilled Nursing”, which features multiple patient and family member testimonials. Medicare rated the ... the country. Broadway plans to use the video to give future patients a firsthand ...
(Date:6/30/2015)... New York, NY (PRWEB) , ... June 30, ... ... international shipping when buying eyeglasses online , finally its here, ... and offer express shipping rates, for many location, ask about shipping with DHL ...
(Date:6/30/2015)... New York (PRWEB) , ... June 30, 2015 ... ... ( http://www.xareltolawsuit2015.com/ ) currently pending in a federal multidistrict litigation now underway in ... Court convenes its next monthly Status Conference. According to the Court’s calendar, that ...
Breaking Medicine News(10 mins):Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3
... the cost of such tests is a potential stumbling block, ... the heart arteries for calcium deposits can help predict future ... that adding such scans to routine checkups would be worth ... of potential heart trouble, said Dr. Diane Bild, deputy director ...
... Michael D. Farley has,joined the Lupus ... Washington,DC as the organization,s Chief Operating Officer, ... overall organizational administration and,field development. Farley has ... including serving most recently as the,interim CEO ...
... Inc.,(Nasdaq: EMAG ), a leader in ... healthcare networks, announced today that its,HeartSuite(TM) VERICIS(R) ... for,Cardiology PACS*. HeartSuite is Emageon,s comprehensive suite ... information,management, hemodynamic monitoring, advanced visualization and content,management. ...
... PURCELLVILLE, Va., March 26 At a panel,discussion ... Force Colonel,Mike Turner, a candidate for U.S. Congress ... for Professor Judy Feder, his opponent,in the June ... Frank,Wolf in what is expected to be a ...
... Courses Improve Patient Care and Address State Regulations, ... Care Compliance,Strategies, Inc.), the leading provider of online ... with University,HealthSystem Consortium (UHC) to deliver a suite ... 11 courses with multimedia content and,healthcare specific case ...
... of Other Medicare Providers at Risk, WASHINGTON, ... drug plans (PDPs) pay drugstores twice as fast,as ... and its,beneficiaries at least $3.3 billion over the ... (PwC) that was commissioned by the,Pharmaceutical Care Management ...
Cached Medicine News:Health News:Calcium Scans Help Predict Coronary Risk 2Health News:Michael D. Farley Appointed Chief Operating Officer of Lupus Foundation of America, Inc. 2Health News:Emageon Receives 'Best in KLAS' Cardiology PACS Award 2Health News:Democrat Mike Turner Backs Single-Payer Healthcare; Opponent Feder Undecided 2Health News:HCCS Partners With UHC to Deliver Cultural Competency Courses 2Health News:HCCS Partners With UHC to Deliver Cultural Competency Courses 3
The URCA (Uric acid) method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of uric acid in serum, plasma and urine....
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
For the quantitative in vitro determination of Triglycerides in serum and plasma....
Medicine Products: